Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
Positive lymph node (s)
Perineural invasion
Lympho-vascular invasion
Close margins
High risk factors following resection: positive-margin(s)and/or extra nodal extension (ENE)
pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0)
Patients receiving Neo-adjuvant or concurrent Chemotherapy
Non-Squamous Histology
All India Institute of Medical Sciences
Lead sponsor
Indian Council of Medical Research
Collaborator